REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 149 filers reported holding REATA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $32,331,108 | +13.0% | 317,096 | +0.8% | 1.42% | +3.1% |
| Q1 2023 | $28,605,341 | +10.8% | 314,621 | -53.7% | 1.37% | +9.9% |
| Q4 2022 | $25,824,538 | +90.9% | 679,772 | +26.3% | 1.25% | +78.8% |
| Q3 2022 | $13,526,000 | +55.5% | 538,252 | +88.1% | 0.70% | +56.2% |
| Q2 2022 | $8,697,000 | -2.0% | 286,181 | +5.7% | 0.45% | +32.2% |
| Q1 2022 | $8,873,000 | +88.1% | 270,846 | +51.4% | 0.34% | +94.3% |
| Q4 2021 | $4,717,000 | -83.0% | 178,872 | -35.2% | 0.17% | -82.8% |
| Q3 2021 | $27,784,000 | -20.3% | 276,155 | +12.1% | 1.01% | -20.6% |
| Q2 2021 | $34,879,000 | +33.8% | 246,443 | -5.7% | 1.27% | +35.1% |
| Q1 2021 | $26,068,000 | +163.2% | 261,467 | +311.9% | 0.94% | +117.8% |
| Q2 2020 | $9,903,000 | -40.1% | 63,472 | -44.6% | 0.43% | -54.8% |
| Q1 2020 | $16,532,000 | -20.8% | 114,536 | +12.2% | 0.96% | +8.4% |
| Q4 2019 | $20,874,000 | -8.1% | 102,109 | -63.9% | 0.88% | -16.8% |
| Q3 2019 | $22,707,000 | -37.9% | 282,818 | -27.0% | 1.06% | -27.8% |
| Q2 2019 | $36,548,000 | +9.1% | 387,369 | -1.2% | 1.47% | +7.7% |
| Q1 2019 | $33,512,000 | +27.0% | 392,089 | -16.7% | 1.36% | +5.0% |
| Q4 2018 | $26,391,000 | -31.8% | 470,431 | -0.6% | 1.30% | -8.7% |
| Q3 2018 | $38,695,000 | +102.8% | 473,275 | -13.2% | 1.42% | +97.5% |
| Q2 2018 | $19,077,000 | +88.4% | 545,520 | +10.5% | 0.72% | +77.3% |
| Q1 2018 | $10,127,000 | -36.3% | 493,753 | -12.1% | 0.41% | -33.8% |
| Q4 2017 | $15,908,000 | -10.2% | 561,736 | -1.3% | 0.61% | -14.9% |
| Q3 2017 | $17,709,000 | +37.7% | 569,416 | +40.1% | 0.72% | +34.1% |
| Q2 2017 | $12,859,000 | +53.4% | 406,426 | +9.8% | 0.54% | +56.1% |
| Q1 2017 | $8,385,000 | +17.4% | 370,199 | +13.2% | 0.34% | +12.8% |
| Q4 2016 | $7,142,000 | +12.5% | 327,147 | +35.8% | 0.30% | +7.8% |
| Q3 2016 | $6,350,000 | +91.8% | 240,878 | +43.7% | 0.28% | +78.0% |
| Q2 2016 | $3,310,000 | – | 167,610 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |